Zim LaboratoriesNSE:ZIMLAB -2.32%76 PEG Ratio is 58.31 as of Jun. 27, 2026, which is 1463% above its 10-year median of 3.73. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 347 Drug Manufacturers companies, Zim Laboratories ranks worse than 98.27% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Zim Laboratories's PEG Ratio or its related term are showing as below:
NSE:ZIMLAB'
s PEG Ratio Range Over the Past 10 Years
Min: 1.19 Med: 3.73 Max: 59.71
Current: 58.32
During the past 12 years, Zim Laboratories's highest PEG Ratio was 59.71. The lowest was 1.19. And the median was 3.73.
NSE:ZIMLAB's PEG Ratio is ranked worse than 98.27% of 347
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs NSE:ZIMLAB: 58.32
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Zim Laboratories (NSE:ZIMLAB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Zim Laboratories PEG Ratio Related Terms
Zim Laboratories PEG Ratio Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Zim Laboratories (NSE:ZIMLAB) has a PEG Ratio of 58.31 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zim Laboratories and its competitors. This is 1463% above median its historical median of 3.73. Over the past decade, Zim Laboratories' PEG Ratio has ranged from 1.19 to 59.71. According to the industry distribution chart, Zim Laboratories ranks #341 out of 347 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Zim Laboratories' PEG Ratio too high?
Zim Laboratories' current PEG Ratio of 58.31 is 1463% above median its 10-year median of 3.73. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 59.71. The Drug Manufacturers industry median PEG Ratio is 1.71. Zim Laboratories' value of 58.31 is 3309.9% above this industry median. Based on the distribution chart, Zim Laboratories ranks #341 out of 347 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #341 out of 347 companies for PEG Ratio. This places Zim Laboratories in the lower half of its industry. The industry median PEG Ratio is 1.71. Zim Laboratories' value of 58.31 is 3309.9% above this benchmark. Historically, Zim Laboratories' own PEG Ratio has ranged from 1.19 to 59.71 over the past decade. While the company's 10-year median is 3.73 vs. the industry median of 1.71, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current PEG Ratio of 58.31 is 3309.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current PEG Ratio is 58.31, which is 1463% above median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current PEG Ratio is 58.31, which is 1463% above median its 10-year median of 3.73 and 3309.9% above the Drug Manufacturers industry median of 1.71. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current PEG Ratio is 58.31 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
PEG Ratio: 58.31 (1463% above median its 10-year median of 3.73)
GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
Industry Position: 3309.9% above the Drug Manufacturers median (#341 of 347)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score
Get the complete analysis for NSE:ZIMLAB
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
